Delving into the Latest Updates on Anti-CD20/CD30 CAR-T Cells(Shanghai First Song Biotechnology) with Synapse

Overview

Basic Info

Drug Type

CAR-T

Synonyms-

Target

Mechanism

CD20 modulators(B-lymphocyte antigen CD20 modulators), CD30 modulators(Tumor necrosis factor receptor superfamily member 8 modulators)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication

B-Cell Malignant NeoplasmRefractory Lymphoma

Inactive Indication-

Originator Organization

Shanghai First Song Therapeutics Co., Ltd

Active Organization

Shanghai First Song Therapeutics Co., Ltd

Inactive Organization-

Drug Highest PhaseEarly Phase 1

First Approval Date-

Regulation-

Login to view timeline

This is a single-center, single-arm, open-label, exploratory study to determine the safety, tolerability, feasibility, and preliminary anti-tumor activity of anti-CD19-CAR-T cells in subjects with relapsed/refractory (r/r) B-cell malignancies.
This study plans to enroll patients with relapsed/refractory CD19-positive B-cell malignancies, who will receive a single infusion of anti-CD19-CAR-T cells after screening, PBMC collection, and lymphodepleting chemotherapy.

Start Date24 Aug 2023

Sponsor / Collaborator

Shanghai First Song Therapeutics Co., Ltd

NCT06532643 / RecruitingEarly Phase 1

An Exploratory Clinical Study of Autologous Anti-CD20/CD30 Chimeric Antigen Receptor T Cells (anti-CD20/CD30 CAR-T Cells) in Subjects with Relapsed/Refractory Lymphoma

This study is an exploratory clinical trial of a single-center, open-label, single-dose treatment of anti-CD20/CD30-CAR-T cells in subjects with relapsed/refractory lymphoma.

Start Date24 Aug 2023

Sponsor / Collaborator

Shanghai First Song Therapeutics Co., Ltd

100 Clinical Results associated with Anti-CD20/CD30 CAR-T Cells(Shanghai First Song Biotechnology)

Login to view more data

100 Translational Medicine associated with Anti-CD20/CD30 CAR-T Cells(Shanghai First Song Biotechnology)

Login to view more data

100 Patents (Medical) associated with Anti-CD20/CD30 CAR-T Cells(Shanghai First Song Biotechnology)

Login to view more data

100 Deals associated with Anti-CD20/CD30 CAR-T Cells(Shanghai First Song Biotechnology)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
B-Cell Malignant Neoplasm	Phase 1	CN	Shanghai First Song Therapeutics Co., Ltd	24 Aug 2023
Refractory Lymphoma	Phase 1	CN	Shanghai First Song Therapeutics Co., Ltd	24 Aug 2023